Beta Bionics (NASDAQ:BBNX) Share Price Crosses Below Two Hundred Day Moving Average – What’s Next?

Shares of Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report) passed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $14.86 and traded as low as $14.55. Beta Bionics shares last traded at $14.72, with a volume of 1,075,548 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages recently commented on BBNX. Leerink Partners increased their price objective on shares of Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, September 14th. Bank of America raised their price objective on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. Wells Fargo & Company initiated coverage on Beta Bionics in a report on Wednesday, September 23rd. They set an “overweight” rating and a $28.00 price target for the company. William Blair began coverage on shares of Beta Bionics in a research note on Friday, August 21st. They issued a “market perform” rating for the company. Finally, Piper Sandler reissued an “overweight” rating and issued a $24.00 price target (up from $20.00) on shares of Beta Bionics in a report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and an average price target of $23.69.

Read Our Latest Report on BBNX

Beta Bionics Stock Performance

The firm has a 50-day moving average price of $18.17 and a two-hundred day moving average price of $14.86.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.01. The company had revenue of $35.51 million for the quarter. Beta Bionics had a negative net margin of 65.31% and a negative return on equity of 27.33%. On average, equities research analysts predict that Beta Bionics, Inc. will post -2.04 EPS for the current year.

Insider Activity

In related news, CFO Stephen Feider sold 6,675 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the transaction, the chief financial officer directly owned 159,378 shares in the company, valued at $3,045,713.58. The trade was a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 36,870 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total value of $680,620.20. Following the completion of the sale, the insider owned 87,157 shares in the company, valued at approximately $1,608,918.22. This represents a 29.73% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 103,844 shares of company stock valued at $2,026,928. 5.30% of the stock is owned by company insiders.

Institutional Trading of Beta Bionics

Several institutional investors have recently modified their holdings of BBNX. BlackRock Inc. purchased a new stake in shares of Beta Bionics during the second quarter worth approximately $52,340,000. Eversept Partners LP lifted its stake in shares of Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after purchasing an additional 736,576 shares during the last quarter. Bank of America Corp DE purchased a new position in Beta Bionics during the second quarter worth about $8,566,000. Perceptive Advisors LLC boosted its position in shares of Beta Bionics by 39.8% during the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares during the period. Finally, Bruce & Co. Inc. acquired a new stake in shares of Beta Bionics in the first quarter valued at $5,518,000.

About Beta Bionics

(Get Free Report)

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.

Further Reading

Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.